Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Depreciation & Amortization (CF) (2020 - 2022)

Historic Depreciation & Amortization (CF) for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q4 2022 value amounting to $104000.0.

  • Atea Pharmaceuticals' Depreciation & Amortization (CF) rose 138571.43% to $104000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $260000.0, marking a year-over-year increase of 79655.17%. This contributed to the annual value of $416000.0 for FY2024, which is 0.0% changed from last year.
  • As of Q4 2022, Atea Pharmaceuticals' Depreciation & Amortization (CF) stood at $104000.0, which was up 138571.43% from $106000.0 recorded in Q3 2022.
  • Atea Pharmaceuticals' Depreciation & Amortization (CF)'s 5-year high stood at $106000.0 during Q3 2022, with a 5-year trough of $4000.0 in Q1 2020.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $7000.0 (2021), whereas its average is $25666.7.
  • The largest annual percentage gain for Atea Pharmaceuticals' Depreciation & Amortization (CF) in the last 5 years was 141428.57% (2022), contrasted with its biggest fall of 0.0% (2022).
  • Quarter analysis of 3 years shows Atea Pharmaceuticals' Depreciation & Amortization (CF) stood at $6000.0 in 2020, then grew by 16.67% to $7000.0 in 2021, then soared by 1385.71% to $104000.0 in 2022.
  • Its Depreciation & Amortization (CF) stands at $104000.0 for Q4 2022, versus $106000.0 for Q3 2022 and $43000.0 for Q2 2022.